{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Butyrate&page=16",
    "query": {
      "intervention": "Butyrate",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 816,
    "total_pages": 82,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Butyrate&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Butyrate&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T13:35:01.988Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00666796",
      "title": "A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "Placebo ethanol",
          "type": "DRUG"
        },
        {
          "name": "Ethanol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2005-04",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2021-02-02",
      "last_synced_at": "2026-10-25T13:35:01.988Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00666796"
    },
    {
      "nct_id": "NCT01664910",
      "title": "CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Allogeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bendamustine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Inotuzumab Ozogamicin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 27,
      "start_date": "2012-10-29",
      "completion_date": "2023-06-28",
      "has_results": true,
      "last_update_posted_date": "2024-07-23",
      "last_synced_at": "2026-10-25T13:35:01.988Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01664910"
    },
    {
      "nct_id": "NCT00141388",
      "title": "To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seizure Disorder, Partial"
      ],
      "interventions": [
        {
          "name": "Pregabalin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 455,
      "start_date": "1998-07",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2009-11-06",
      "last_synced_at": "2026-10-25T13:35:01.988Z",
      "location_count": 48,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141388"
    },
    {
      "nct_id": "NCT02063217",
      "title": "Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Amyloid-beta"
      ],
      "interventions": [
        {
          "name": "Sodium Oxybate",
          "type": "DRUG"
        },
        {
          "name": "Sleep deprivation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-12",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2018-04-26",
      "last_synced_at": "2026-10-25T13:35:01.988Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02063217"
    },
    {
      "nct_id": "NCT01495923",
      "title": "Steroids Versus Gabapentin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sciatica",
        "Radiculopathy"
      ],
      "interventions": [
        {
          "name": "epidural steroid injection",
          "type": "PROCEDURE"
        },
        {
          "name": "Sham epidural steroid injection",
          "type": "PROCEDURE"
        },
        {
          "name": "Gabapentin",
          "type": "DRUG"
        },
        {
          "name": "Placebo gabapentin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "17 Years to 100 Years"
      },
      "enrollment_count": 145,
      "start_date": "2011-12",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2017-04-11",
      "last_synced_at": "2026-10-25T13:35:01.988Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Baltimore, Maryland • Bethesda, Maryland",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495923"
    },
    {
      "nct_id": "NCT00588159",
      "title": "Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Gabapentin",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michelle Kinney",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 146,
      "start_date": "2007-06",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2016-05-04",
      "last_synced_at": "2026-10-25T13:35:01.988Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00588159"
    },
    {
      "nct_id": "NCT06097676",
      "title": "An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Abuse Potential"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arbor Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 86,
      "start_date": "2021-09-28",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-10-25T13:35:01.988Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06097676"
    },
    {
      "nct_id": "NCT01058642",
      "title": "Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postherpetic Neuralgia"
      ],
      "interventions": [
        {
          "name": "ADL5747",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pregabalin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 41,
      "start_date": "2010-01",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2015-07-30",
      "last_synced_at": "2026-10-25T13:35:01.988Z",
      "location_count": 1,
      "location_summary": "West Palm Beach, Florida",
      "locations": [
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01058642"
    },
    {
      "nct_id": "NCT05128344",
      "title": "A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spasms, Infantile"
      ],
      "interventions": [
        {
          "name": "AMZ002 injectable solution, 0.5mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Vigabatrin, oral",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amzell",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "2 Months to 24 Months"
      },
      "enrollment_count": 0,
      "start_date": "2023-04",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2023-04-20",
      "last_synced_at": "2026-10-25T13:35:01.988Z",
      "location_count": 12,
      "location_summary": "Aurora, Colorado • Miami, Florida • Orlando, Florida + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05128344"
    },
    {
      "nct_id": "NCT02040532",
      "title": "Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Menopause",
        "Hot Flashes",
        "Vasomotor Disturbance"
      ],
      "interventions": [
        {
          "name": "Gabapentin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 65 Years · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2014-01",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2019-08-07",
      "last_synced_at": "2026-10-25T13:35:01.988Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02040532"
    }
  ]
}